HUMAN NEURAL CELLS · 2026
A pooled CRISPR program perturbed ASH1L across neural progenitors and glutamatergic and GABAergic neuronal states. A separate ASH1L-specific experiment found increased Ki-67 signal in progenitors.
Fernandez Garcia et al. ↗GENE & BIOLOGY · DEVELOPMENTAL MODELS
Use models to define questions—not to predict a person.
Human neural-cell and mouse studies support context-dependent roles in progenitor behavior, differentiation, synaptic refinement, circuit excitability, and memory stabilization. Species, genotype, lineage, developmental stage, and assay remain attached to every result.
DEVELOPMENTAL MODEL EVIDENCE
Developmental models
Human neural-cell and mouse studies, limits on translation to people, and the unresolved steps needed to reach clinically useful mechanisms.
DIRECT NEURAL & DEVELOPMENTAL MODELS
Direct developmental models
The convergent lesson is context dependence—not one universal neural pathway. Human neural cells and mouse models support roles in progenitor behavior, differentiation, synaptic refinement, circuit excitability, and memory stabilization. Each result is bounded by species, genotype, lineage, developmental stage, and assay.
CORTICAL DEVELOPMENT · MOUSE
Germline and cortical-lineage Ash1l loss changed developmental structure, progenitor dynamics, and cortical-neuron fate, including SATB2-positive populations.
Toolan et al. 2025 ↗SYNAPTIC REFINEMENT · MOUSE
Ash1l haploinsufficiency altered EphA7-linked synaptic refinement and selected behavioral readouts in mice.
Yan et al. 2022 ↗CIRCUIT EXCITABILITY · MOUSE
Prefrontal-cortex perturbation changed chromatin and synaptic-gene programs, neuronal activity, excitation–inhibition balance, and seizure-related phenotypes.
Qin et al. 2021 ↗MEMORY STABILIZATION · MOUSE
A thalamocortical study placed ASH1L late in a CAMTA1–TCF4–ASH1L sequence required to maintain selected memories over weeks, rather than for initial formation.
Terceros et al. 2026 ↗No decisive glia-specific ASH1L deletion-and-rescue study currently establishes a cell-autonomous astrocyte, microglial, or oligodendrocyte mechanism.
Muscle, epidermis, bone, immune, blood, repair, and fly cardiac models demonstrate context-specific functions. They suggest assays to test; they do not establish a human organ-system effect.
Cellular and mouse rescue endpoints provide experimental evidence. They are not treatment recommendations, dosing guidance, or evidence of human benefit.
WHAT BIOLOGY CANNOT YET ANSWER
Six gaps stand between gene-level certainty and a clinically useful mechanism.
A strong research program makes these gaps explicit, tests them in order, and revises a hypothesis when correction, rescue, replication, or human relevance does not support it.
ALLELE OUTPUT
Which transcripts and protein products remain for each molecular finding?
DIRECT LOCI
Which ASH1L-bound regulatory regions change in each relevant human cell state?
CELL VULNERABILITY
Which progenitor, neuronal, glial, or extra-neural states cross a functional dosage threshold?
DEVELOPMENTAL TIMING
When does reduced dosage matter most, and which effects remain reversible?
RESCUE
Does genetic correction or calibrated ASH1L restoration normalize molecular and cellular readouts?
LINK TO HUMAN FUNCTION
Which reproducible measure links a cellular mechanism to meaningful human function?